StockNow
Calendar
Log in
U.S. Markets

Johnson & Johnson (JNJ) announces Caplyta (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal phase 3 study

ORIGINAL · NewsquawkJohnson & Johnson (JNJ) announces Caplyta (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal phase 3 studyRead originalHide original

Caplyta meets key secondary endpoint with greater CGI-S improvement at week 3.

StockNow breaking-news AI analysis

Johnson & Johnson reported a week-three CGI-S secondary-endpoint result for Caplyta in a second pivotal Phase 3 bipolar-mania study; detailed results are unavailable.

News detail

Caplyta meets key secondary endpoint with greater CGI-S improvement at week 3.

1 stocks
JNJJohnson & Johnson$284.39Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Nvidia (NVDA) CEO's relationship with Alice Huang dated back to at least 2023 and facillitated the sale of at least USD 7.5bln in Nvidia chips to China, The Information reports citing sources

NVDAU.S. Markets

Anthropic (ANT) expects IPO price of USD 70-78/shr; to sell 801.35mln IPO shares, with the co. seeking to raise USD 64.4bln. To price on November 18th, and trade on November 19th

AMDAVGOGOOGLGeopolitics

An Iranian diplomatic source denies reports of an agreement with the US on uranium enrichment at 3.67% or other nuclear issues, insisting Tehran's two-day proposal remains unchanged and no detailed nuclear discussions have taken place, according to Avash